PL2011869T3 - Nowe przeciwciało anty-CD98 - Google Patents

Nowe przeciwciało anty-CD98

Info

Publication number
PL2011869T3
PL2011869T3 PL07741116T PL07741116T PL2011869T3 PL 2011869 T3 PL2011869 T3 PL 2011869T3 PL 07741116 T PL07741116 T PL 07741116T PL 07741116 T PL07741116 T PL 07741116T PL 2011869 T3 PL2011869 T3 PL 2011869T3
Authority
PL
Poland
Prior art keywords
antibody
novel anti
novel
Prior art date
Application number
PL07741116T
Other languages
English (en)
Inventor
Tomoyuki Tahara
Yoshikatsu Kanai
Hitoshi Endou
Shiro Kataoka
Kazumasa Hasegawa
Tetsuya Yoshino
Original Assignee
Kyowa Hakko Kirin Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kyowa Hakko Kirin Co Ltd filed Critical Kyowa Hakko Kirin Co Ltd
Publication of PL2011869T3 publication Critical patent/PL2011869T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Physics & Mathematics (AREA)
  • Oncology (AREA)
  • Plant Pathology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
PL07741116T 2006-04-06 2007-04-05 Nowe przeciwciało anty-CD98 PL2011869T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2006105013 2006-04-06
EP07741116.3A EP2011869B1 (en) 2006-04-06 2007-04-05 Novel anti-cd98 antibody
PCT/JP2007/057680 WO2007114496A1 (ja) 2006-04-06 2007-04-05 新規抗ｃｄ９８抗体

Publications (1)

Publication Number Publication Date
PL2011869T3 true PL2011869T3 (pl) 2014-11-28

Family

ID=38563755

Family Applications (1)

Application Number Title Priority Date Filing Date
PL07741116T PL2011869T3 (pl) 2006-04-06 2007-04-05 Nowe przeciwciało anty-CD98

Country Status (12)

Country Link
US (4) US7943745B2 (pl)
EP (2) EP2011869B1 (pl)
JP (2) JP4324637B2 (pl)
KR (1) KR101370164B1 (pl)
CN (2) CN101460623B (pl)
AU (1) AU2007232706B2 (pl)
CA (1) CA2648618C (pl)
ES (1) ES2489641T3 (pl)
PL (1) PL2011869T3 (pl)
PT (1) PT2011869E (pl)
TW (1) TWI390034B (pl)
WO (1) WO2007114496A1 (pl)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI390034B (zh) * 2006-04-06 2013-03-21 Kyowa Hakko Kirin Co Ltd Novel anti-CD98 antibody
GB0615662D0 (en) * 2006-08-07 2006-09-13 Affitech As Antibody
CN103038255A (zh) * 2010-03-26 2013-04-10 国立大学法人德岛大学 新抗cd98抗体及其用途
BR112013014949B1 (pt) 2010-12-15 2021-12-28 Inter-University Research Institute Corporation Research Organization Of Information And Systems Métodos para a produção de uma proteína de interesse e para a obtenção de uma suspensão de células cho capaz de sobreviver e proliferar em um meio sem soro que produz uma proteína de interesse
CN103339255A (zh) 2010-12-15 2013-10-02 协和发酵麒麟株式会社 蛋白质的生产方法
WO2012141285A1 (ja) * 2011-04-15 2012-10-18 ジェイファーマ株式会社 乳癌のバイオマーカー
RU2014124530A (ru) * 2011-11-23 2015-12-27 Идженика, Инк. Антитела к cd98 и способы их применения
WO2013177101A2 (en) * 2012-05-22 2013-11-28 Bristol-Myers Squibb Company Bispecific antibodies and methods of using the same
CA2875451A1 (en) * 2012-06-08 2013-12-12 Kinki University Antibody against transporter and use thereof
US9650411B2 (en) 2012-08-07 2017-05-16 Kyowa Hakko Kirin Co., Ltd. Method of purifying protein
EP3189623A4 (en) * 2014-09-05 2018-05-09 Hewlett-Packard Enterprise Development LP Firewall port access rule generation
EP3290051B1 (en) * 2015-04-30 2019-10-23 Toray Industries, Inc. Pharmaceutical composition for treating and/or preventing cancer
PT3336185T (pt) * 2015-08-10 2022-01-27 Univ Osaka Anticorpo
CN105385694B (zh) * 2015-11-20 2019-01-18 中国人民解放军第四军医大学 抗人cd98单克隆抗体98-3h3轻、重链可变区基因及其应用
CN105754952B (zh) * 2016-02-16 2020-07-10 中国农业科学院兰州兽医研究所 抗羊痘病毒k3l蛋白c末端的单克隆抗体及其应用
WO2021020474A1 (ja) 2019-07-31 2021-02-04 協和キリン株式会社 吸着剤を用いた抗体の精製方法
WO2022252167A1 (en) * 2021-06-02 2022-12-08 Huahui Health Ltd. Anti-cd98 antibodies and uses thereof
EP4442828A4 (en) 2021-11-30 2025-11-12 Daiichi Sankyo Co Ltd Masked antibodies cleavable by protease
CN115772541A (zh) * 2021-12-17 2023-03-10 百奥赛图江苏基因生物技术有限公司 Cd98hc基因人源化非人动物的构建方法及应用
WO2023153442A1 (ja) 2022-02-09 2023-08-17 第一三共株式会社 環境応答性マスク抗体及びその利用

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI884924L (fi) 1987-10-28 1989-04-29 Oncogen Humanimmuglobulin som producerats med hybrid-dna-teknik.
US6001358A (en) 1995-11-07 1999-12-14 Idec Pharmaceuticals Corporation Humanized antibodies to human gp39, compositions containing thereof
JP4689781B2 (ja) * 1998-09-03 2011-05-25 独立行政法人科学技術振興機構 アミノ酸輸送蛋白及びその遺伝子
US6342219B1 (en) * 1999-04-28 2002-01-29 Board Of Regents, The University Of Texas System Antibody compositions for selectively inhibiting VEGF
IL155977A0 (en) * 2000-11-30 2003-12-23 Medarex Inc Transgenic transchromosomal rodents for making human antibodies
WO2003001884A2 (en) * 2001-06-26 2003-01-09 Trustees Of Tufts College Targeting tumor cell antigens: antibodies useful for the diagnosis, prognosis, and treatment of cancer
ES2524694T3 (es) 2002-10-17 2014-12-11 Genmab A/S Anticuerpos monoclonales humanos contra CD20
HN2004000285A (es) * 2003-08-04 2006-04-27 Pfizer Prod Inc ANTICUERPOS DIRIGIDOS A c-MET
AR045563A1 (es) * 2003-09-10 2005-11-02 Warner Lambert Co Anticuerpos dirigidos a m-csf
JP4606110B2 (ja) 2004-10-05 2011-01-05 日本電産サーボ株式会社 モータファン
TWI390034B (zh) * 2006-04-06 2013-03-21 Kyowa Hakko Kirin Co Ltd Novel anti-CD98 antibody
GB0615662D0 (en) * 2006-08-07 2006-09-13 Affitech As Antibody

Also Published As

Publication number Publication date
PT2011869E (pt) 2014-07-09
US9051374B2 (en) 2015-06-09
EP2011869B1 (en) 2014-06-11
US20100143367A1 (en) 2010-06-10
CN101460623B (zh) 2012-06-27
TWI390034B (zh) 2013-03-21
WO2007114496A1 (ja) 2007-10-11
JP2009189376A (ja) 2009-08-27
CN102659947A (zh) 2012-09-12
CA2648618A1 (en) 2007-10-11
US8486402B2 (en) 2013-07-16
AU2007232706B2 (en) 2014-01-09
ES2489641T3 (es) 2014-09-02
TW200808962A (en) 2008-02-16
KR101370164B1 (ko) 2014-03-24
JPWO2007114496A1 (ja) 2009-08-20
KR20090026258A (ko) 2009-03-12
US20140037636A1 (en) 2014-02-06
CN101460623A (zh) 2009-06-17
US7943745B2 (en) 2011-05-17
JP4324637B2 (ja) 2009-09-02
JP5160501B2 (ja) 2013-03-13
EP2527437A1 (en) 2012-11-28
EP2011869A4 (en) 2010-03-17
AU2007232706A1 (en) 2007-10-11
EP2011869A1 (en) 2009-01-07
CN102659947B (zh) 2015-10-21
US20110280884A1 (en) 2011-11-17
CA2648618C (en) 2016-06-21
US9688770B2 (en) 2017-06-27
US20150307621A1 (en) 2015-10-29

Similar Documents

Publication Publication Date Title
PT2011869E (pt) Novo anticorpo anti-cd98
EP2138576A4 (en) ANTI-CLAUDIN-4 ANTIBODY
PT2146745E (pt) Anticorpo pentaespecífico
IL187106A (en) Sclerostin binds antibody
IL190472A0 (en) Anti-glypican-3 antibody
IL192266A0 (en) Anti-ilt7 antibody
GB0708002D0 (en) Antibodies
SI2200700T1 (sl) Nova protitelesa
IL194236A0 (en) Antibody purification
IL185366A0 (en) Antibody
EP1987067A4 (en) ANTIBODY FORMULATION
IL197487A0 (en) Improved immunoassay methods
GB0615662D0 (en) Antibody
IL205073A0 (en) Anti-bst2 antibody
GB0718737D0 (en) Antibodies
GB0702888D0 (en) Novel Antibodies
IL198744A0 (en) Novel antiproliferation antibodies
GB0517487D0 (en) Antibodies
SI2062053T1 (sl) Izboljšani imunotestni postopki
EP1896047A4 (en) ANTI-GFRALPHA3 ANTIBODIES
GB0505489D0 (en) Antibodies
GB0505054D0 (en) Antibodies
GB0512278D0 (en) Antibodies
GB0607376D0 (en) Antibodies
GB0606276D0 (en) Antibodies